MedTrace Logo

Correcting Hypocapnia in Aneurysmal Subarachnoid Hemorrhage.

NCT07343232 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2026-01-15

No results posted yet for this study

Summary

Based on the clinical observation that over half of the patients in the management of aneurysmal subarachnoid hemorrhage(aSAH) present with spontaneous hyperventilation, which is significantly associated with delayed cerebral ischemia and poor neurological outcomes, this prospective pilot study is designed to investigate the safety and efficacy of normobaric facemask oxygen for hypocapnia in aSAH.

Conditions

  • Aneurysmal Subarachnoid Hemorrhage (aSAH)

Interventions

BEHAVIORAL

Normobaric Facemask Oxygen

Oxygen is to be delivered via a rebreathing facemask (ensuring no one-way valve is present), with a fractional inspired oxygen (FiO2) of 25-41% and an oxygen flow rate of ≤ 5 L/min. The goals are to maintain patient SpO2 \> 95%, PaCO2 between 35-42 mmHg, and, where feasible (particularly in centers with the capability for monitoring), an intracranial pressure (ICP) of \< 15 mmHg.

BEHAVIORAL

control group

Using nasal cannula for oxygen inhalation or not using oxygen inhalation at all. Monitor and record the patient's SpO2, systolic blood pressure, diastolic blood pressure, PaCO2, and also monitor the intracranial pressure (ICP) at a center with monitoring capabilities.

Sponsors & Collaborators

  • The Chinese University of Hong Kong, Shenzhen

    lead OTHER

Principal Investigators

  • Renzhi Wang, MD · CUHK-Shenzhen

  • Xinyu Yang · CUHK-Shenzhen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-09-30
Completion
2026-10-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07343232 on ClinicalTrials.gov